Ixsys: Synthesis over structure

A traditional hurdle in developing drugs has been identifying the molecule with the optimal therapeutic effect. Although several companies have attempted to overcome this problem by laboratory modifications such as antibody humanization, the optimization process has remained time-consuming, costly and complex. Often it still results in a protein or antibody with lower affinity for its target, high production costs and a poor therapeutic index.

With Ixsys Inc.'s Synthesis-Based Molecular Design (SBMD) technology, molecules are designed through the generation of

Read the full 789 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers